title: Low- versus high-dose rituximab for antibody-mediated rejection after kidney transplantation.
authors.forename: Julie
authors.initials: J
authors.lastname: Bellière
authors.forename: Lionel
authors.initials: L
authors.lastname: Rostaing
authors.forename: Céline
authors.initials: C
authors.lastname: Guilbeau-Frugier
authors.forename: Nicolas
authors.initials: N
authors.lastname: Congy
authors.forename: Nassim
authors.initials: N
authors.lastname: Kamar
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate; D006084:Graft Rejection / Q000188:drug therapy*; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D006680:HLA Antigens; D007155:Immunologic Factors; D000069283:Rituximab